問卷

TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Infectious Disease

更新時間:2023-09-19

王秉槐
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

44Cases

2026-03-15 - 2032-10-25

Phase III

Active
ROSETTA Lung-202: A randomized, double-blind, Phase 3 trial comparing pumitamig monotherapy with pembrolizumab as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer and PD-L1 expression ≥ 50%.
  • Condition/Disease

    Comparison of Pumitamig monotherapy versus Pembrolizumab as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer and PD-L1 expression ≥ 50%.

  • Test Drug

    BMS-986545

Participate Sites
5Sites

Recruiting5Sites

2020-06-20 - 2027-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting9Sites

Terminated1Sites

2022-02-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2023-09-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2024-01-01 - 2030-06-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-04-15 - 2033-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting11Sites

2024-05-31 - 2027-05-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-01-29 - 2031-11-15

Phase II/III

Active
AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • Condition/Disease

    Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Test Drug

    PF-07275315 Placebo

Participate Sites
7Sites

Recruiting7Sites

2025-06-09 - 2029-11-26

Active
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation
  • Condition/Disease

    Pulmonary Disease, Chronic Obstructive

  • Test Drug

    預充填式注射劑

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5